{"id":"W2107174064","doi":"10.1016/s1473-3099(03)00545-0","title":"Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management","year":2003,"lang":"en","type":"review","venue":"The Lancet Infectious Diseases","topic":"Tuberculosis Research and Epidemiology","field":"Medicine","cited_by":751,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre; Eli Lilly (Canada); Novartis (Canada); University of Alberta; Pfizer (Canada); University Health Network","funders":"","keywords":"Medicine; Infliximab; Tuberculosis; Etanercept; Tuberculin; Tumor necrosis factor alpha; Latent tuberculosis; Immunology; Disease; Adalimumab; Biologic Agents; Risk factor; Mycobacterium tuberculosis; Intensive care medicine; Internal medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.115822244171784,"score_gpt":0.4315433494883175,"score_spread":0.3157211053165335,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}